TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06471387

Intervention type: BEHAVIORAL
Intervention: Flexiquit Smoking Cessation Intervention
Description: Participants will enter a 6-week (once weekly) self-delivered computerized intervention program called Flexiquit. Developed and validated by Clinical Psychologists of the Department of Psychology at the University of Cyprus, Flexiquit is an avatar-led app designed to support smoking cessation. It aims to assist with abstinence and monitor participants' progress through personalized modules and assessments.

Intervention type: BEHAVIORAL
Intervention: Flexiquit Smoking Cessation Intervention
Description: Participants will enter a 6-week (once weekly) self-delivered computerized intervention program called Flexiquit. Developed and validated by Clinical Psychologists of the Department of Psychology at the University of Cyprus, Flexiquit is an avatar-led app designed to support smoking cessation. It aims to assist with abstinence and monitor participants' progress through personalized modules and assessments.
Study: NCT05049317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic FTME surgery
Description: Nerve plane was defined as the overlying tiny membranous tissue including the nerves, the adipose tissue and the extremely tiny capillaries around the nerve. Following the TME principles, the surgical procedure of FTME was guided by the nerve plane and dissected between the proper fascia of the rectum and nerve plane (the first gap), which could ensure completeness of the nerve plane and the proper fascia of the rectum.
Study: NCT05887778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9% Inj
Description: administration of 5ml 0,9% sodium chloride - 30 minutes before the supraclavicular brachial plexus block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,1mg/kg Dexamethasone
Description: administration of 0,1mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,2mg/kg Dexamethasone
Description: administration of 0,2mg/kg Dexamethasone - 30 minutes before the supraclavicular brachial plexus block
Study: NCT06089096

Intervention type: DIAGNOSTIC_TEST
Intervention: Home Sleep Apnea test (HSAT)
Description: Patient will received HSAT at baseline
Study: NCT04136782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel combined with carboplatin
Description: Albumin-bound paclitaxel combined with carboplatin: Albumin-bound paclitaxel (Abraxis BioScience, LLC., Mclrose Park, IL, USA; certificate number: H20091059) will be intravenously administered at 125 mg/m2 for 30 minutes on days 1 and 8 of each 21-day session of treatment. There will be six 21-day sessions of treatment. At the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; National Drug Approval Number: H20020181) will be intravenously administered at AUC = 2 mg•min/mL for 120 minutes on days 1 and 8 of each 21-day session of treatment. Carboplatin must be hydrated for 3 days before use to prevent nephrotoxicity.
Study: NCT05771870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Description: Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After understanding about the study, two master's degree students from Karabük University Institute of Graduate Studies of Child Health and Diseases Nursing consented to participate on a volunteer basis and became peer mentors in the study. All postgraduate students are pediatric nurses with at least two years of clinical experience who have completed their undergraduate nursing program.
Study: NCT06433674

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water
Description: The placebo group with will receive a similar amount of sterile water in a colored syringe
Study: NCT05771870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse mentoring
Description: Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After providing information about the research to bachelor's degree nurses who have worked in the Children's Units of Karabuk Training and Research Hospital for at least two years, two mentors for the nurse mentoring group were chosen on a volunteer basis. Mentors were taught on the concept of mentoring, the roles of the mentor, interpersonal relationships, and communication skills prior to the study.
Study: NCT04136782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin combined with docetaxel
Description: Epirubicin (Pfizer Pharmaceutical (Wuxi) Co., Ltd., China; National Drug Approval Number: H20000496) will be intravenously administered at 90 mg/m2 for 120 minutes on day 1 of each 21-day session of treatment. At the same time, docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; National Drug Approval Number: J20150083) will be intravenously administered at 75 mg/m2 for 120 minutes. Drug administration will be performed once every other 3 weeks for four times.
Study: NCT05846607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention oral supplement
Description: The oral supplement used as intervention for the study will be DongzheSutang(DAISY FSMP,Jiangsu,China). The formula contains only carbohydrate:12.5g in 100ml of product(glucose syrup and maltodextrin)，with a caloric density of 16.32kcal/g.
Study: NCT04381182

Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo Wearable Device
Description: Participants wear Apollo device which generates vibration frequencies on skin and can be controlled by the user
Study: NCT04697745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal dexamethasone
Description: intrathecal adjuvants to bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal dexmedetomidine
Description: intrathecal adjuvants to bupivacaine
Study: NCT05921045

Intervention type: OTHER
Intervention: modification of clinical approach in clinical practice at time 0
Description: evaluation of modification in clinical approach after training

Intervention type: OTHER
Intervention: modification of clinical approach in clinical practice at 6 months
Description: evaluation of modification in clinical approach after retraining
Study: NCT06230354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT05668988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD9008
Description: orally, 300 mg, once daily until a treatment discontinuation criterion is met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed+carboplatin
Description: Participants randomized into chemotherapy arm can receive up to 6 cycles of pemetrexed + carboplatin (pemetrexed 500 mg/m2 + carboplatin area under the plasma concentration-time curve 5 mg/ml per minute (AUC5), IV infusion, every 3 weeks) as the initial treatment. Participants whose disease has not progressed after 4 cycles of first-line platinum-based doublet chemotherapy may receive pemetrexed maintenance monotherapy until a treatment discontinuation criterion is met.
Study: NCT06058208

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation
Description: Olfactory stimulation: Mothers will be made to smell their babies' odor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation
Description: Olfactory stimulation: Mothers will be made to smell their babies' odor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual stimulation
Description: Mothers will be shown video images of their babies.
Study: NCT05859737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disaster Preparedness Education Program
Description: The SIMAH Program includes interactive group training for three months, public education materials prepared by AFAD, and reminder phone messages will apply.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Disaster and Emergency Management Presidency Education
Description: Public education materials prepared by the Disaster and Emergency Management Presidency (AFAD) will give.
Study: NCT04479371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Injecting liposomal bupivacaine for a penile block for analgesia for hypospadias repair

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Standard bupivacaine
Study: NCT06289205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be utilised in two different ways to prevent development of proliferative vitreoretinopathy after vitrectomy for rhegmatogenous retinal detachment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be utilised in two different ways to prevent development of proliferative vitreoretinopathy after vitrectomy for rhegmatogenous retinal detachment
Study: NCT06113380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NTUH-ii, am upper limb rehabilitation robot arm
Description: Rehabilitation programs are planned based on the subject's capabilities, and the differences between assisted rehabilitation with a robot and traditional rehabilitation are compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional upper limb physical therapy
Description: Traditional upper limb physical therapy is performed by the therapist.
Study: NCT05469698

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tobacco Treatment Research Program Standard Care
Description: Participants interested in quitting tobacco will be offered standard tobacco cessation care including nicotine replacement therapy and counseling.
Study: NCT05800431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive neuromodulation through the Nesa device
Description: patients receive non-invasive neurostimulation through the Nesa device
Study: NCT05207345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional programme
Description: 90-minute session divided into:~* 45 minutes of core stability treatment~* 45 minutes of general rehabilitation (active / active, assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General exercise programme
Description: 90 minutes of general rehabilitation (active / active assisted / passive mobilization, stretching, posture maintenance, postural and autonomy training, cycle ergometer, exercise bike and ambulatory training).
Study: NCT06391983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training (elastic band)
Description: The intervention group attended online group education sessions on diabetes self management, as well as resistance exercise training sessions three times weekly; the sessions were approximately 40 minutes long and included 5 minutes of warm up, followed by 30 minutes of resistance exercises and 5 minutes of cool down. The resistance training consisted of ten upper-body and lower-body exercises using elastic band. The initial sessions were 1 to 2 sets of 6 to 8 repetitions at 45% of the one-repetition maximum (1 RM). It was increased progressively to 2 to 3 sets of 8 to 12 approximately 50% -55% of 1 RM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance training (elastic band)
Description: The intervention group attended online group education sessions on diabetes self management, as well as resistance exercise training sessions three times weekly; the sessions were approximately 40 minutes long and included 5 minutes of warm up, followed by 30 minutes of resistance exercises and 5 minutes of cool down. The resistance training consisted of ten upper-body and lower-body exercises using elastic band. The initial sessions were 1 to 2 sets of 6 to 8 repetitions at 45% of the one-repetition maximum (1 RM). It was increased progressively to 2 to 3 sets of 8 to 12 approximately 50% -55% of 1 RM.
Study: NCT04920708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib 300mg
Description: Ipatasertib 300mg once daily. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant 500g
Description: Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant 500g
Description: Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant 500g
Description: Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant 500g
Description: Fulvestrant 500mg administered intramuscularly in the buttocks slowly (1-2 minutes per injection) as two 5-mL injections (one in each buttock). Administered days 1 and 15 of Cycle 1. For subsequent cycles, patients will receive fulvestrant as described above in the clinic on Day 1 of each cycle or approximately every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib 75mg-125mg
Description: Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 75mg-125mg
Description: Palboclicib 75mg-125mg once daily, dependent on toxicities. Oral administration. Treatment is continuous daily for 21 days, followed by 7 days off, to complete a 28 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDK4/6 Inhibitor
Description: CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDK4/6 Inhibitor
Description: CDK4/6 inhibitor. As per current standard of care regime for ER+/HER2- breast cancer.
Study: NCT06681324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7798
Description: AZD7798

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04884724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptive Dance Exercise Program
Description: It is planned to include balance, stabilization, mobility, speed and rhythm activities for the exercises applied in Cerebral Palsy rehabilitation and based on the principles of motor learning, and to apply the dance steps and figures to be applied with visual and auditory stimuli.
Study: NCT05712564

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire for fatigue assessment

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire for fatigue assessment
Study: NCT06722248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high fidelity simulation-based training
Description: The intervention is a two-hour high-fidelity simulation training session focusing on newborn assessment, care practices, skin-to-skin contact, and breastfeeding. It uses SimBaby mannequins and breastfeeding models to mimic the hospital environment. Scenarios are tailored to nursing students' learning levels and reviewed by experienced midwives.~The training includes:~Prebriefing: Introduction of learning objectives, scenario background, simulation familiarization, confidentiality discussions, and ground rules.~Intervention: Scenario-based training on baby care and breastfeeding. Debriefing: Plus-delta debriefing model reviewed by simulation educators. The training will be conducted in the nursing simulation laboratory.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional training
Description: Conventional training includes lecture, tutorial and basic lab with low-fidelity mannequins.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional training
Description: Conventional training includes lecture, tutorial and basic lab with low-fidelity mannequins.
Study: NCT06733636

Intervention type: OTHER
Group type: OTHER
Intervention: Sudoku Puzzles
Description: Sudoku puzzles of consistent and regular difficulty

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ScentCare (Olfactory Training Device)
Description: ScentCare is a smell training device with eight encapsulated scents housed in separate compartments and is contained using a charcoal filter, which will be dispersed in the base of our device to prevent smell contamination in the user's environment. The outer casing contains an opening that can be manually rotated to line up with the casing on each scent. This is facilitated by a rod in the center of the device, which serves as the axis of rotation. By pressing the capsule, the desired scent is released through a hole in the casing, similar to the mechanism of a pen. The user presses the compartment back downwards into the casing when done. The ScentCare mobile application offers clear instructions for at-home smell training and testing, with features like scent randomization to prevent users from getting accustomed to a specific order. It provides detailed guidance on device use and allows users to schedule sessions and receive daily reminders, ensuring a structured training regimen.
Study: NCT06736743

Intervention type: DIAGNOSTIC_TEST
Intervention: SMART Tool for Feeding Skill Assessment
Description: Infant Oral Feeding Skill Assessment (FSA) done using SMART Tool
Study: NCT06771674

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Given as monotherapy.

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Given as monotherapy.

Intervention type: DRUG
Intervention: Nivolumab
Description: Given in combination with chemotherapy.

Intervention type: DRUG
Intervention: Nivolumab
Description: Given in combination with chemotherapy.

Intervention type: DRUG
Intervention: Nivolumab
Description: Given without chemotherapy.

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Given in combination with chemotherapy.

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Given in combination with chemotherapy.

Intervention type: DRUG
Intervention: Pembrolizumab
Description: Given without chemotherapy.
Study: NCT06770192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calisthenics
Description: Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes. Session would be of 8 minutes in which 1 minutes exercise and 1 minute rest is there. Exercise include bunny jumps, bear crawls , crab walk and mad cat and 9 minutes cool down period. This protocol would be follow up to 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric
Description: : Session will start with 9 minutes of warm up which includes 4 minutes of jogging and moderate intensity dynamic stretching for 5 minutes.. And 9 minutes cool down period. Following Plyometrics would be performed:1 medicine ball squats 2.ABC pushups 3.Medicine ball chest press 4.standing jump reach for star 5.SINGLE leg hops 6.Pushup on knees 7.zig zag double jump

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: compare with other groups
Study: NCT06774872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine 100Mg Tab and Lamivudine 300 Mg Tab
Description: Participants randomised in the arm 1 will receive the DORAVIRINE/LAMIVUDINE combination: doravirine (PIFELTRO®) 100 mg 1 pill a day + lamivudine 300 mg 1 pill a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir 50mg Tab and Lamivudine 300 Mg Tab
Description: Participants randomised in the arm 2 will receive the DTG/3TC combination: dolutegravir 50 mg/lamivudine 300 mg (DOVATO®) 1 pill a day
Study: NCT06770881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN033
Description: JSKN033 should be administered subcutaneously on the first day of each week cycle/ each 2-week cycle
Study: NCT06772948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asynchronised group
Description: Health workers with musculoskeletal system disorders will be given pilates exercises asynchronously using the YouTube application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronized group
Description: Using the Zoom application, healthcare workers with musculoskeletal disorders will perform pilates exercises synchronously.